# Article Title

Latest News from Pharma-Watch

Actos bladder cancer evidence keeps European Medicines Agency hesitant

European Medicines Agency remains cautious toward pioglitazone, but hesitates to issue outright ban despite Actos bladder cancer evidence (Oct. 25, 2011) After earlier sending signals that it might

FDA gives Class 1 designation to CareFusion's ventilator recall

CareFusion EnVe ventilator recall hit with FDA Class 1 ‘most grave’ designation (Oct. 19, 2011) CareFusion Corp. today announced that its voluntary recall of 128 EnVe ventilators made late last year

Pradaxa could be drug meriting skeptical eye

Are storm clouds already gathering over Pradaxa?Critics of blood-thinner drug troubled by events in New Zealand (Oct. 18, 2011) If some safety advocates are correct, a drug worth keeping a skeptical eye

Some drug, medical device makers to be shielded from lawsuits if Wisconsin legislature OKs bill

Wisconsin legislature mulls bill to restrict lawsuits against some drug, med-device makers (Oct. 17, 2011) Wisconsin Public Radio reports that a measure introduced in the Wisconsin legislature proposes

Uprizing 2.0 removed from market in voluntary recall

Use of banned superdrol as ingredient means Uprizing 2.0 now gone from market (Oct. 12, 2011) – A nutritional supplement in capsule form used by bodybuilders as an aid to increasing muscle mass has been